Third Harmonic Bio, Inc. (THRD)
Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Ms. Natalie C. Holles | CEO & Director | 930.25k | -- | 1973 |
| Mr. Christopher M. Murphy | Chief Financial & Business Officer | 673.03k | -- | 1984 |
| Ms. Jennifer Dittman | Chief Operating Officer | -- | -- | 1982 |
| Ms. Julie Person | Chief Administrative Officer | 574k | -- | 1974 |
| Mr. Steven P. Sweeney | Senior Vice President of Development Operations | -- | -- | -- |
| Dr. Edward R. Conner M.D. | Chief Medical Officer | 672k | -- | 1973 |
| Mr. Dennis Dean Ph.D. | Chief Non-Clinical Development Officer | -- | -- | 1962 |
| Ommer Chohan | Treasurer & Secretary | -- | -- | -- |
Third Harmonic Bio, Inc.
- Sector:
- Healthcare
- Industry: Biotechnology
- Full Time Employees:
- 31
Description
Third Harmonic Bio, Inc., a biopharmaceutical company, focuses on the development of the medicine for the treatment of dermal, respiratory, and gastrointestinal inflammatory diseases. The company develops oral small-molecule inhibitors of KIT, a cell surface receptor that serves as the master regulator of mast cell function and survival. It also develops THB335, an oral small molecule KIT inhibitor for the treatment of mast cell-mediated inflammatory diseases, respiratory, and gastrointestinal conditions. It has a license agreement with Novartis Pharma AG. The company was formerly known as Project IGE, Inc. and changed its name to Third Harmonic Bio, Inc. in June 2019. Third Harmonic Bio, Inc. was incorporated in 2019 and is headquartered in San Francisco, California.
Corporate Governance
Upcoming Events
August 6, 2025 at 12:30 PM UTC - August 11, 2025 at 12:30 PM UTC
Third Harmonic Bio, Inc. Earnings Date